HAL (France)
open access
Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy
ABSTRACT Background Unmet needs remain for disease‐modifying interventions for the treatment of severe persistent food allergies. In mice models, abatacept, a cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4) immunoglobulin fusion protein, promotes immune tolerance to food proteins, and suppresse
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Identification of Anaphylactogenic Antibodies in Peanut Allergy#1349617
- A new experimental model of peanut allergy in BALB/c and C57BL/6 mice#1235421
- Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy#855663
- Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis#891857
- Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age#876723
Record · ID 1312560
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive